News Jiangsu Yahong Meditech Co., Ltd.

Equities

688176

CNE100005XW0

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
6.71 ^CNY	-1.76%		+1.36%	-37.76%

Apr. 29	Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	Tranche Update on Jiangsu Yahong Meditech Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Tranche Update on Jiangsu Yahong Meditech Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	Apr. 01	CI
Asieris Pharmaceuticals Announces Release of Positive Results from Multicenter Phase III Global Clinical Study	Mar. 18	CI
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Asieris Pharmaceuticals to Unveil First-Ever Results of the International Multicenter Phase III Clinical Study for 1702, a Non-Surgical Treatment for Cervical HSIL, at the 2024 EUROGIN	Feb. 22	CI
Jiangsu Yahong Meditech to Buy Back Shares for Up to 100 Million Yuan	Feb. 12	MT
Jiangsu Yahong Meditech Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	Feb. 06	CI
Jiangsu Yahong Meditech Co., Ltd. authorizes a Buyback Plan.	Feb. 05	CI
Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, A Bladder Cancer Diagnosis and Management Drug, At the 2024 ASCO-GU	Jan. 29	CI
Asieris Pharmaceuticals Announces Set-Up of the Women's Health Business Unit for Commercialization	Jan. 08	CI
Asieris Pharmaceuticals Appoints Sophia Cao as Senior Vice President and Head of the Women's Health Business Unit	Jan. 08	CI
Certain A Shares of Jiangsu Yahong Meditech Co., Ltd. are subject to a Lock-Up Agreement Ending on 7-JAN-2024.	Jan. 06	CI
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Asieris Pharmaceuticals Unveils Results of Its Hexvix[®] (Apl-1706) Phase III Clinical Trial in China	23-10-12	CI
Photocure Partner Asieris Pharmaceuticals to Present First Results for its Hexvix Phase III Clinical Trial in China at the SIU2023 Annual Meeting	23-10-07	CI
Jiangsu Yahong Meditech Completes Phase III Trial Into APL1702 Drug; Shares Drop 4%	23-09-21	MT
Asieris Pharmaceuticals Announces the First Non-Vaccine Investigational Product for Cervical HSIL Has Achieved Its Primary Endpoint	23-09-20	CI
Jiangsu Yahong Meditech Co., Ltd.(XSSC:688176) added to S&P Global BMI Index	23-09-18	CI
Jiangsu Yahong Meditech Enrolls First Subjects for Ulcerative Colitis Drug Trial	23-09-15	MT
Jiangsu Yahong Meditech Gets Nod to Trial Ulcerative Colitis Drug	23-08-30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Jiangsu Yahong Meditech Co., Ltd.

Equities

688176

CNE100005XW0

Summary

Filters